Assessing quality of life in medical trials on patients with inflammatory bowel disease

Annals of Gastroenterology

Volumn 13, Issue 4, 2000, Pages 261-263

  Mouzas, I Al ^a,b   Pallis, A G ^a  

^a UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; NARCOTIC AGENT; PENTOSA; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CROHN DISEASE; DAILY LIFE ACTIVITY; DISEASE SEVERITY; ENTERITIS; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; LONG TERM CARE; MEDLINE; PARENTERAL NUTRITION; QUALITATIVE ANALYSIS; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SCORING SYSTEM; SEXUAL BEHAVIOR; SHORT FORM 36; SLEEP PATTERN; SOCIAL BEHAVIOR; TOTAL COLON RESECTION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

EID: 0008739253     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Drossman DA. Psychosocial considerations in gastroenterology. In Sleisenger MH, Fordtran JS eds. Gastrointestinal disease: pathophysiology, diagnosis and management 6th ed. Philadelphia: WB, Saunders 1995.
2. O'Young J, McPeek B. Quality of life variables in surgical trials. J Chron Dis 1987; 40:513-522.
3. Nymman M, Hansson I, Eriksson S. Long term immunosuppressive treatment in Crohn's disease. Scand J Gastroenterol 1985; 20:1197-1203.
4. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of IBD. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994; 106:287-296.
5. Greenberg GR, Feagan BG, Martin F and the Canadian IBD Study Group. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331:836-841.
6. Singleton JW, Hanauer S, Robinson M. Quality of life results of a double blind, placebo controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995; 40:931-935.
7. Bar-Meir S, Chowers Y, Lave A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide study group. Gastroenterology 1998; 115:835-840.
8. Rutgeers P, D'Haens G, Targan S et al. Efficacy and safety of retreatment with anti tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's Disease. Gastroenterology 1999; 117:761-769.
9. Jeppesen PB, Langholz E, Mortensen PB. Quality of life in patients receiving home parenteral nutrition. Gut 1999; 44:844-852.
10. Richards DM, Irving MH. Assessing the quality of life of patients with intestinal failure on home parenteral nutrition. Gut 1997; 40:218-222.
11. Somerville KW, Langman MJ, Kane SP, MacGilchrist AJ, Watkinson G. Effect of treatment on symptoms and quality of life in patients with ulcerative colitis: comparative trial of hydrocortisone acetate foam and prednisolone 21-phosphate enemas. BMJ 1985; 291:866-869.
12. Robinson M, Hanauer S, Hoop R, Zbrozek A, Wilkinson C. Mesalamine capsules enhances the quality of life for patients with ulcerative colitis. Aliment Pharmacol Ther 1994; 8:27-34.
13. Cohen RD, Brodsky Al, Hanauer SB. A comparison of the quality of life in patients with severe ulcerative colitis after total colectomy versus medical treatment with intravenous cyclosporin Inflamm Bowel Dis 1999; 5:1-10.